AMAG Pharmaceuticals Inc. (NASDAQ:AMAG)‘s stock had its “outperform” rating reiterated by investment analysts at Leerink Swann in a report issued on Thursday. They currently have a $36.00 price target on the specialty pharmaceutical company’s stock. Leerink Swann’s price target suggests a potential upside of 52.80% from the stock’s previous close.
Several other equities research analysts have also recently weighed in on AMAG. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 5th. Jefferies Group reduced their target price on shares of AMAG Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating for the company in a research note on Wednesday, August 10th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. AMAG Pharmaceuticals presently has an average rating of “Buy” and an average target price of $36.33.
AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 23.56 on Thursday. The company’s market capitalization is $804.67 million. AMAG Pharmaceuticals has a 52 week low of $17.92 and a 52 week high of $42.49. The firm’s 50-day moving average price is $24.05 and its 200-day moving average price is $23.94.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.20 by $0.25. AMAG Pharmaceuticals had a negative net margin of 4.87% and a positive return on equity of 13.98%. The business earned $127.40 million during the quarter, compared to analysts’ expectations of $128.52 million. During the same quarter last year, the company earned $1.12 earnings per share. The firm’s revenue was up 46.7% on a year-over-year basis. On average, equities analysts expect that AMAG Pharmaceuticals will post $5.55 earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its position in shares of AMAG Pharmaceuticals by 528.5% in the first quarter. BlackRock Inc. now owns 4,299 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 3,615 shares in the last quarter. Teacher Retirement System of Texas boosted its position in AMAG Pharmaceuticals by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 4,864 shares of the specialty pharmaceutical company’s stock worth $116,000 after buying an additional 589 shares during the period. Nisa Investment Advisors LLC boosted its position in AMAG Pharmaceuticals by 1,666.7% in the third quarter. Nisa Investment Advisors LLC now owns 5,300 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 5,000 shares during the period. Mason Street Advisors LLC purchased a new position in AMAG Pharmaceuticals during the second quarter worth about $162,000. Finally, Societe Generale purchased a new position in AMAG Pharmaceuticals during the second quarter worth about $232,000.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.